Wang-Dong Xu

Prof. Wang-Dong Xu

Department of Evidence-Based Medicine, Southwest Medical University, Luzhou, Sichuan, China.

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
YTYang-Yang Tang
Yang-Yang Tang
DWDa-Cheng Wang
Da-Cheng Wang
YWYou-Qiang Wang
You-Qiang Wang
AHAn-Fang Huang
An-Fang Huang
WXWang-Dong Xu
Wang-Dong Xu
Hypoxia-inducible factor-1α (HIF-1α) is a primary metabolic sensor, and is expressed in different immune cells, such as macrophage, dendritic cell, neutrophil, T cell, and non-immune cells, for instance, synovial fibroblast, and islet β cell. HIF-1α signaling regulates cellular metabolism, triggering the release of inflammatory cytokines and inflammatory cells proliferation. It is known that microenvironment hypoxia, vascular proliferation, and impaired immunological balance are present in autoimmune diseases. To date, HIF-1α is recognized to be overexpressed in several inflammatory autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and function of HIF-1α is dysregulated in these diseases. In this review, we narrate the signaling pathway of HIF-1α and the possible immunopathological roles of HIF-1α in autoimmune diseases. The collected information will provide a theoretical basis for the familiarization and development of new clinical trials and treatment based on HIF-1α and inflammatory autoimmune disorders in the future.

31 October 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ZYZhi-Chao Yuan
Zhi-Chao Yuan
WXWang-Dong Xu
Wang-Dong Xu
XLXiao-Yan Liu
Xiao-Yan Liu
XLXing-You Liu
Xing-You Liu
AHAn-Fang Huang
An-Fang Huang
LSLin-Chong Su
Lin-Chong Su
Interleukin (IL)-36 is a member of the IL-1 superfamily and includes three agonists (IL-36α, IL-36β, and IL-36γ) and an antagonist (IL-36Ra). IL-36 agonists bind to heterodimeric receptor complexes. Then, the heterotrimer complexes signal via intracellular functional domains, binding to downstream signaling proteins and inducing inflammatory responses. In this review, we summarized the current knowledge about the biological role of IL-36 and its correlation with systemic inflammatory diseases. The information collected will help to increase the understanding of the potential of IL-36 and may give clues for developing novel therapeutic strategies.

1 July 2018 in Autoimmunity Reviews
Verified
Journal Article
Closed access
LSLin-Chong Su
Lin-Chong Su
XLXiao-Yan Liu
Xiao-Yan Liu
AHAn-Fang Huang
An-Fang Huang
WXWang-Dong Xu
Wang-Dong Xu

1 March 2020 in Autoimmunity Reviews
Verified
Journal Article
Closed access
LSLin-Chong Su
Lin-Chong Su
WXWang-Dong Xu
Wang-Dong Xu
AHAn-Fang Huang
An-Fang Huang

8 January 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JWJia-Min Wang
Jia-Min Wang
WXWang-Dong Xu
Wang-Dong Xu
ZYZhi-Chao Yuan
Zhi-Chao Yuan
QWQian Wu
Qian Wu
JZJie Zhou
Jie Zhou
AHAn-Fang Huang
An-Fang Huang
This study aimed to discuss association between serum Angiopoietin2 (Ang2) levels, Ang2 gene polymorphisms and systemic lupus erythematosus (SLE) susceptibility. It was carried out by 235 SLE, 342 other inflammatory autoimmune diseases patients and 380 healthy individuals. Serum Ang2 levels was examinated by ELISA, and Ang2 rs12674822, rs1823375, rs1868554, rs2442598, rs3739390 and rs734701 polymorphisms were genotyped using KASP. Increased Ang2 concentrations in SLE patients were observed compared with healthy controls and patients with other inflammatory autoimmune diseases. For allelic contrast, except for rs1823375 (P = 0.058) and rs2442598 (P = 0.523), frequencies of alleles for other polymorphisms were significantly different between SLE patients and controls. Genotypes for rs12674822 (TT), rs1868554 (TT, TA and TT+TA), rs734701 (TT) were negatively correlated with SLE susceptibility (OR = 0.564 for rs12674822; OR = 0.572, OR = 0.625, OR = 0.607 for rs1868554; OR = 0.580 for rs734701). Patients carrying rs1868554 T allele and rs3739390 G allele were more likely to develop hematuria (P = 0.039; P = 0.003). The G allele frequencies of rs12674822 and rs2442598 were higher in SLE patients with proteinuria (P = 0.043; P = 0.043). GC genotype frequency of rs3739390 was higher in patients with ds-DNA (+) (P = 0.024). In summary, SLE had increased serum Ang2, which may be a potential biomarker, and the polymorphisms correlated with SLE.

20 October 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
WXWang-Dong Xu
Wang-Dong Xu
LSLin‐Chong Su
Lin‐Chong Su
XLXiao‐Yan Liu
Xiao‐Yan Liu
JWJia‐Min Wang
Jia‐Min Wang
ZYZhi‐Chao Yuan
Zhi‐Chao Yuan
AHAn-Fang Huang
An-Fang Huang
IL‐38 is a newly identified cytokine that belongs to the IL‐1 family. In our previous study, we found elevated plasma levels of IL‐38 in patients with systemic lupus erythematosus (SLE). However, the clear relationship of IL‐38 expression in plasma, peripheral blood mononuclear cells (PBMCs) and clinical and laboratory features needs elucidation. Additionally, we evaluated the possible role of IL‐38 in regulating production of inflammatory cytokines in PBMCs in vitro. A pristane‐induced murine lupus model was used to further demonstrate the effects of IL‐38 on cytokines in vivo and discuss the significance of IL‐38 in lupus development. The results showed that mRNA expression of IL‐38 in PBMCs of patients with SLE was elevated compared with volunteers, and expression of IL‐38 in both plasma and PBMCs was strongly related to clinical features, such as haematuria and proteinuria, and correlated with a SLEDAI score. Plasma levels of TNF‐α, IL‐1β, IL‐6 and IL‐23 were elevated in patients with SLE and were related to plasma levels of IL‐38. In vitro, PBMCs of patients with SLE stimulated with IL‐38 showed a decreased expression of the four inflammatory cytokines compared with PBMCs of patients without treatment. Interestingly, IL‐38 administration in lupus mice significantly reduced the development of lupus, such as reduced proteinuria, improved histological examinations of the kidneys and down‐regulated inflammatory cytokines. In conclusion, IL‐38 may suppress synthesis of pro‐inflammatory cytokines and therefore regulate lupus pathogenesis.